It seems that a couple of people who’ve taken Tysabri (Alentuzumab) after having taken Fingolimod are at what they’ve called ‘increased risk of treatment failure’. It seems that these 2 individuals have developed a severe CNS condition. It’s curable with plasmapheresis - removing antibodies from the blood, but it’s not a good outcome at all. It does seem that what’s being reported is problems after a few months on Tysabri. So if you’ve been on it for a good while, even if you took Fingolimod first, you should be in the clear. But no reason not to check with your neurologist if you’re worried.
Oh. Silly of me. They do have stupid names. I wish someone would pick a name and stick to it. Surely we can handle long names? Lemtrada used to be Campath, which is of course Alemtuzumab. Actually, now the blogspot article makes more sense. (With regard to autoimmunities that is!)
Thanks for that. Now where is that edit button so I can change the title of the thread? Oh, yes I forgot, there isn’t one!
PS nothing much to do with my MS, I am just a bit thick, although in all seiousness I have found that my ability to take in complex or complicated information is more restricted in recent years.